BACKGROUND: Childhood cancer survivors (CCS) are at elevated risk of secondary malignancies (SM). Enhanced screening for SM is recommended, but compliance is poor. We hypothesized that CCS with adult-onset SM (colorectal cancer [CRC], melanoma, or breast cancer [BC]) would present with more advanced disease and have decreased overall survival (OS). METHODS: The Surveillance, Epidemiology, and End Results Program was queried for patients diagnosed with cancer at age less than or equal to 18 also diagnosed with adult-onset CRC, melanoma, or BC. A cohort without a history of prior malignancy was likewise identified. Tumor features and clinical outcomes were compared. RESULTS: CCS with a SM (n = 224) were compared with patients without a childhood cancer history (n = 1,392,670). CCS were diagnosed younger (BC = 37.6 vs. 61.3, p < 0.01, CRC = 35.0 vs. 67.1, p < 0.01, melanoma = 29.6 vs. 61.3 years old, p < 0.01). CCS with BC were more likely to have Stage III or IV disease (25.2% vs. 16.5%, p = 0.01). Hormone-receptor expression also differed; CCS were less likely to develop Luminal A-type tumors (48.6% vs. 66.9%, p = 0.01). After age-adjustment, CCS had worse OS (Hazard ratio: CRC = 2.449, p < 0.01, melanoma = 6.503, p < 0.01, BC = 3.383, p < 0.01). CONCLUSION: CCS were younger when diagnosed with a SM. After age-adjustment, OS was diminished. Heightened surveillance may be necessary for CCS diagnosed with SM.
BACKGROUND: Childhood cancer survivors (CCS) are at elevated risk of secondary malignancies (SM). Enhanced screening for SM is recommended, but compliance is poor. We hypothesized that CCS with adult-onset SM (colorectal cancer [CRC], melanoma, or breast cancer [BC]) would present with more advanced disease and have decreased overall survival (OS). METHODS: The Surveillance, Epidemiology, and End Results Program was queried for patients diagnosed with cancer at age less than or equal to 18 also diagnosed with adult-onset CRC, melanoma, or BC. A cohort without a history of prior malignancy was likewise identified. Tumor features and clinical outcomes were compared. RESULTS: CCS with a SM (n = 224) were compared with patients without a childhood cancer history (n = 1,392,670). CCS were diagnosed younger (BC = 37.6 vs. 61.3, p < 0.01, CRC = 35.0 vs. 67.1, p < 0.01, melanoma = 29.6 vs. 61.3 years old, p < 0.01). CCS with BC were more likely to have Stage III or IV disease (25.2% vs. 16.5%, p = 0.01). Hormone-receptor expression also differed; CCS were less likely to develop Luminal A-type tumors (48.6% vs. 66.9%, p = 0.01). After age-adjustment, CCS had worse OS (Hazard ratio: CRC = 2.449, p < 0.01, melanoma = 6.503, p < 0.01, BC = 3.383, p < 0.01). CONCLUSION: CCS were younger when diagnosed with a SM. After age-adjustment, OS was diminished. Heightened surveillance may be necessary for CCS diagnosed with SM.
Authors: Stephanie M Smith; Jennifer S Ford; William Rakowski; Chaya S Moskowitz; Lisa Diller; Melissa M Hudson; Ann C Mertens; Annette L Stanton; Tara O Henderson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Causes Control Date: 2010-05-27 Impact factor: 2.506
Authors: Chaya S Moskowitz; Joanne F Chou; Joseph P Neglia; Ann H Partridge; Rebecca M Howell; Lisa R Diller; Danielle Novetsky Friedman; Dana Barnea; Lindsay M Morton; Lucie M Turcotte; Michael A Arnold; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Tara O Henderson Journal: J Clin Oncol Date: 2019-07-01 Impact factor: 44.544
Authors: Chaya S Moskowitz; Joanne F Chou; Suzanne L Wolden; Jonine L Bernstein; Jyoti Malhotra; Danielle Novetsky Friedman; Nidha Z Mubdi; Wendy M Leisenring; Marilyn Stovall; Sue Hammond; Susan A Smith; Tara O Henderson; John D Boice; Melissa M Hudson; Lisa R Diller; Smita Bhatia; Lisa B Kenney; Joseph P Neglia; Colin B Begg; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-04-21 Impact factor: 44.544
Authors: Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04 Impact factor: 4.254
Authors: Mark A Applebaum; Zalman Vaksman; Sang Mee Lee; Eric A Hungate; Tara O Henderson; Wendy B London; Navin Pinto; Samuel L Volchenboum; Julie R Park; Arlene Naranjo; Barbara Hero; Andrew D Pearson; Barbara E Stranger; Susan L Cohn; Sharon J Diskin Journal: Eur J Cancer Date: 2016-12-26 Impact factor: 9.162
Authors: Tara O Henderson; Chaya S Moskowitz; Joanne F Chou; Angela R Bradbury; Joseph Phillip Neglia; Chau T Dang; Kenan Onel; Danielle Novetsky Friedman; Smita Bhatia; Louise C Strong; Marilyn Stovall; Lisa B Kenney; Dana Barnea; Elena Lorenzi; Sue Hammond; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Lisa R Diller; Kevin C Oeffinger Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Adam P Yan; Yan Chen; Tara O Henderson; Kevin C Oeffinger; Melissa M Hudson; Todd M Gibson; Joseph P Neglia; Wendy M Leisenring; Kirsten K Ness; Jennifer S Ford; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui; Paul C Nathan Journal: J Clin Oncol Date: 2020-03-06 Impact factor: 44.544
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816